Skip to main content
SpringerLink
Log in

Merck has been criticised by the AHF* over the announced price for its key new HIV/AIDS drug, raltegravir [Isentress].

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. AIDS Healthcare Foundation.AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress. Media Release: 15 Oct 2007. Available from: URL: http://www.aidshealth.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merck has been criticised by the AHF* over the announced price for its key new HIV/AIDS drug, raltegravir [Isentress].. Pharmacoecon. Outcomes News 539, 11 (2007). https://doi.org/10.2165/00151234-200705390-00026

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705390-00026

Keywords

Search

Navigation